First Adolescent Migraine Prophylactic Approved

TOPAMAX TABLETS (topiramate) 25mg, 50mg, 100mg, 200mg tablets by Janssen
TOPAMAX TABLETS (topiramate) 25mg, 50mg, 100mg, 200mg tablets by Janssen

The FDA has approved Topamax (topiramate; Janssen) for migraine prophylaxis in adolescents aged 12–17 years old. This is the first drug approval for a migraine prophylactic in this age group.

The safety and effectiveness in preventing migraine headaches in adolescents (ages 12–17) was established in a clinical trial that enrolled 103 patients. Treatment with Topamax resulted in a decrease in migraine frequency of about 72% compared to 44% in participants that were treated with placebo.

RELATED: Pain Management Resource Center

Topamax is already approved as initial monotherapy and adjunct in partial-onset or primary generalized tonic-clonic seizures; as adjunct in Lennox-Gastaut syndrome; and for migraine prophylaxis in adults.

For more information call (800) 526-7736 or visit Topamax.com.